25 min listen
Commercialization Learnings with Novartis Gene Therapies' President Chris Fox
Commercialization Learnings with Novartis Gene Therapies' President Chris Fox
ratings:
Length:
20 minutes
Released:
Sep 1, 2022
Format:
Podcast episode
Description
With 20+ gene therapy targets in Novartis Gene Therapies’ pipeline, President Chris Fox and her team are hyper-focused on newborn screenings as the pathway to helping more and more patients. The company's initial gene therapy, Zolgensma, for spinal muscular atrophy (SMA) has been approved in more than 40 regions and countries and has been used to treat more than 2,300 patients worldwide. Fox details what’s next on the commercialization front for the therapy, and she shares advice with Cell & Gene: The Podcast listeners about what it takes to commercialize a therapy.
Released:
Sep 1, 2022
Format:
Podcast episode
Titles in the series (76)
Advancing Patient Engagement with Novartis Gene Therapies' Dr. Amy Nicole Nayar by Cell & Gene: The Podcast